Onconetix, Inc.
ONCO Healthcare Biotechnology
Onconetix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $815,400.00, down 67.7% from fiscal 2024. In the quarter to June 2026, revenue fell 83.9%, EPS grew 99.5% and free cash flow fell 36.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ONCO
Onconetix, Inc. (ONCO) P/E ratio
As of 16 October 2026, Onconetix, Inc. (ONCO) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (March 2026) to 1.6× (April 2026); the current reading is higher than 87% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | (99.65%) |
| Mar 2026 | 1.3× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | (41.67%) |
| 6 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SLXN Silexion Therapeutics Corp compare | n/m |
| VIVS VivoSim Labs, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| HCWB HCW Biologics Inc. compare | n/m |
| AFMDQ Affimed N.V. compare | n/m |
| ARAV ARAVIVE, INC compare | n/m |
| ONCO Onconetix, Inc. | 0.0× |
| DCOY Decoy Therapeutics Inc compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)